KR101617497B1 - Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물 - Google Patents

Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
KR101617497B1
KR101617497B1 KR1020130068411A KR20130068411A KR101617497B1 KR 101617497 B1 KR101617497 B1 KR 101617497B1 KR 1020130068411 A KR1020130068411 A KR 1020130068411A KR 20130068411 A KR20130068411 A KR 20130068411A KR 101617497 B1 KR101617497 B1 KR 101617497B1
Authority
KR
South Korea
Prior art keywords
leu
ser
pro
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020130068411A
Other languages
English (en)
Korean (ko)
Other versions
KR20130141395A (ko
Inventor
고정민
김기수
이승훈
이영선
김범준
Original Assignee
재단법인 아산사회복지재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 아산사회복지재단 filed Critical 재단법인 아산사회복지재단
Publication of KR20130141395A publication Critical patent/KR20130141395A/ko
Application granted granted Critical
Publication of KR101617497B1 publication Critical patent/KR101617497B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
KR1020130068411A 2012-06-15 2013-06-14 Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물 Active KR101617497B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120064302 2012-06-15
KR20120064302 2012-06-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020160029525A Division KR20160032077A (ko) 2012-06-15 2016-03-11 Slit-Robo 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
KR20130141395A KR20130141395A (ko) 2013-12-26
KR101617497B1 true KR101617497B1 (ko) 2016-05-03

Family

ID=49758487

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020130068411A Active KR101617497B1 (ko) 2012-06-15 2013-06-14 Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물
KR1020160029525A Withdrawn KR20160032077A (ko) 2012-06-15 2016-03-11 Slit-Robo 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020160029525A Withdrawn KR20160032077A (ko) 2012-06-15 2016-03-11 Slit-Robo 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물

Country Status (6)

Country Link
US (1) US9802994B2 (enExample)
EP (2) EP3156074B1 (enExample)
JP (2) JP6100367B2 (enExample)
KR (2) KR101617497B1 (enExample)
CN (1) CN104582727B (enExample)
WO (1) WO2013187730A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138920A (ko) 2016-06-08 2017-12-18 재단법인 아산사회복지재단 Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
WO2020175935A1 (ko) 2019-02-27 2020-09-03 주식회사 대웅제약 알부민이 결합된, slit3 단백질의 lrrd2를 포함하는 골 관련 질환 예방 또는 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2989362T3 (es) * 2014-03-14 2024-11-26 Univ New York State Res Found Regulación neurogénica del crecimiento óseo y degradación ósea
KR101897322B1 (ko) * 2015-01-21 2018-09-10 재단법인 아산사회복지재단 원발성 갑상선암 전이의 진단방법 및 이를 이용한 진단키트
WO2017213435A1 (ko) * 2016-06-08 2017-12-14 재단법인 아산사회복지재단 Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
JP7018458B2 (ja) * 2017-06-02 2022-02-10 ファイザー・インク 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
WO2024061158A1 (en) * 2022-09-20 2024-03-28 Everest Medicines (China) Co., Ltd. Slit2 related compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042289A1 (en) * 2010-09-28 2012-04-05 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bone density related diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
WO2002081745A2 (en) 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
US20110002972A1 (en) * 2007-09-14 2011-01-06 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
EP2036921A1 (en) * 2007-09-14 2009-03-18 Scil Technology GmbH Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042289A1 (en) * 2010-09-28 2012-04-05 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bone density related diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell Tissue Organs Vol.190(2):69-80
GenBank Accession # AAQ89243.1 (2003. 10. 03.) SLIT3*

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138920A (ko) 2016-06-08 2017-12-18 재단법인 아산사회복지재단 Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
US10897923B2 (en) 2016-06-08 2021-01-26 Daewoong Pharmaceutical Co., Ltd. Method using slit-robo system to treat sarcopenia
WO2020175935A1 (ko) 2019-02-27 2020-09-03 주식회사 대웅제약 알부민이 결합된, slit3 단백질의 lrrd2를 포함하는 골 관련 질환 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN104582727B (zh) 2018-04-27
JP6100367B2 (ja) 2017-03-22
US9802994B2 (en) 2017-10-31
WO2013187730A1 (ko) 2013-12-19
KR20130141395A (ko) 2013-12-26
EP3156074A1 (en) 2017-04-19
CN104582727A (zh) 2015-04-29
EP3156074B1 (en) 2019-06-05
JP2015527973A (ja) 2015-09-24
JP6216849B2 (ja) 2017-10-18
EP2862580A4 (en) 2016-06-01
EP2862580A1 (en) 2015-04-22
KR20160032077A (ko) 2016-03-23
US20150175673A1 (en) 2015-06-25
JP2017039729A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
KR101617497B1 (ko) Slit3의 lrr2 유전자 또는 그 발현 단백질을 유효성분으로 함유하는 골절 또는 골다공증 예방 또는 치료용 약학적 조성물
KR101508397B1 (ko) 염증성 장 질환의 검출 방법
US20030129176A1 (en) Atherosclerosis-associated genes
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
US20250283871A1 (en) Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
KR20230124915A (ko) 세포 사멸 유도 dffa 유사 이펙터 b(cideb) 억제제를 이용한 간 질환의 치료
JP2011087587A (ja) ２１個のヒト分泌タンパク質
EP1174149A1 (en) Proliferation inhibitor for androgen-independent tumor
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
KR20070092737A (ko) 임신 합병증의 진단 및 치료에 유용한 핵산 및 폴리펩티드
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
JP2003514541A (ja) １８個のヒト分泌タンパク質
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
KR20080068147A (ko) 암 치료의 효능을 증진시키는 방법
KR100865801B1 (ko) 암 치료의 효능을 증진시키는 방법
CN109414504B (zh) 药物组合物或食品组合物及评价活性成分体内效果的方法
US7462447B2 (en) Methods for evaluating susceptibility to a bone homeostasis disorder
AU2013276994B2 (en) IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
KR20130047874A (ko) 골 손실 진단 마커로서의 피브리노겐의 용도
JP2005224188A (ja) 骨代謝異常疾患に関連した転写因子に制御される遺伝子の選抜法とその利用
Colin et al. 1, 25-dihydroxyvitamin D3 modulates dexamethasone effects by changing TH1/TH17 and TH2 cytokine production by peripheral blood mononuclear cells in early rheumatoid arthritis patients
Class et al. Patent application title: FIBROSIS SUSCEPTIBILITY IL22RA2 GENE AND USES THEREOF Inventors: Alain Dessein (Marseille, FR) Mathieu Sertorio (Saint Ismier, FR) Laurent Argiro (Marseille, FR) Assignees: UNIVERSITE D'AIX-MARSEILLE
Nicolaije et al. Disturbed mesenchymal stem cell differentiation and osteoporotic like features in ageing male DNA repair deficient TTD mice
Bruedigam et al. The osteoporotic effects of rosiglitazone are not caused by a direct negative action on human osteoblast differentiation
Alves et al. Protein expression analysis of a human osteoblast differentiation model

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190401

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10